{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_openai import ChatOpenAI\n",
    "import os\n",
    "from dotenv import load_dotenv\n",
    "from openai import OpenAI\n",
    "import nest_asyncio\n",
    "nest_asyncio.apply()\n",
    "import asyncio  # Add this import\n",
    "import os\n",
    "from dotenv import load_dotenv\n",
    "import json\n",
    "from APIs.combinedapi import PubMedProcessor\n",
    "\n",
    "\n",
    "\n",
    "openai_client = OpenAI(api_key=\"OPENAI_API_KEY\")\n",
    "\n",
    "\n",
    "load_dotenv()\n",
    "\n",
    "llm = ChatOpenAI()\n",
    "\n",
    "llm = ChatOpenAI(api_key=\"OPENAI_API_KEY\" )\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "chatgpt_system_prompt = \"\"\"# IMPORTANT:\n",
    "Try to answer this question/instruction with step-by-step thoughts and make the answer more structural.\n",
    "Use `\\n\\n` to split the answer into several paragraphs.\n",
    "Just respond to the instruction directly. DO NOT add additional explanations or introducement in the answer unless you are asked to.\n",
    "'''Develop a scientific rationale for the following:\n",
    "                             \n",
    "                             You are a AI assistant with a background in drug discovery.\n",
    "\n",
    "    Given target: Gamma secretase\n",
    "    Given disease: Alzheimer's disease\n",
    "    Given mode of action: Gamma secretase is a multi-subunit protease complex that cleaves type I transmembrane proteins, including the amyloid precursor protein (APP) leading to the generation of amyloid-beta (Aβ) peptides.\n",
    "\n",
    "    Context:\n",
    "     Aβ is a family of secreted peptides generated from the sequential cleavages of the type 1 membrane protein APP by beta-secretase (BACE) and gamma-secretase (GSEC), respectively. \n",
    "      BACE cleaves APP in the luminal domain, releasing the N-terminal soluble APPβ domain and leaving the C-terminal fragment, APP-CTF, which remains in the membrane. \n",
    "      Subsequently, the APP-CTF is recruited to GSEC, a complex comprising four subunits, including PS, which harbors the active site. GSEC first cuts APP-CTF at the epsilon-cleavage site located close to the inner leaflet of the membrane. \n",
    "      This cleavage event produces either Aβ48 or Aβ49 and the APP intracellular domain (AICD). The membrane-retained Aβ48 or Aβ49 is then further processed by GSEC in a continuous cascade of proteolytical events at every third of fourth amino acid, where the N-terminal product of each reaction becomes the substrate for the next GSEC cleavage event.\n",
    "       Accordingly, GSEC processes APP-CTF along two main product lines, Aβ49 → 46 → 43 → 40 → 37… and Aβ48 → 45 → 42 → 38…, respectively (Takami et al., 2009; Matsumura et al., 2014; Olsson et al., 2014). During this processing cascade, Aβ43 and shorter Aβ peptides stochastically escape further processing by GSEC and are released into the extracellular space. \n",
    "      As a result, Aβ peptides varying from 30 to 43 amino acids in length are secreted into the extracellular space. Among all secreted Aβ, Aβ40 is the most abundant in human CSF, followed by Aβ38, Aβ42, and Aβ37 (Liu et al., 2022). In cognitively normal individuals, Aβ42 and Aβ43 represent a smaller portion of the total secreted Aβ (Liu et al., 2022).\n",
    "         These longer forms of Aβ seed the formation of Aβ-amyloid aggregates, a key step in the formation of amyloid plaques (Veugelen et al., 2016), as illustrated in Figure 1. Aβ42, which is produced in higher amounts than Aβ43, is the most abundant Aβ in amyloid plaques (Welander et al., 2009).\n",
    "\n",
    "\n",
    "    Task 1: Develop a scientific rationale for Gamma secretase in Alzheimer's disease.\n",
    "\n",
    "    Highlight the working hypothesis for the clinical target rationale and human biology evidence by minimum 2000 words.\n",
    "\n",
    "    Describe as much as possible the evidence in humans or in human tissue that link the target, target space or approach to the pathogenesis of interest.\n",
    "    If known, also describe here the wanted mode of action with regards to desired clinical outcome.\n",
    "    Please avoid including only pre-clinical data in this section.\n",
    "\n",
    "    Use the following structure and provide a detailed description for each point:\n",
    "    - Working hypothesis:\n",
    "    - Create a detailed description of the following idea: Develop an inhibitor of the neurokinin 3 receptor (NK3R) GPCR for the treatment of vasomotor symptoms due to menopause.\n",
    "    - Is there are significant unmet medical need?\n",
    "    - Is it suitable for combination therapy?\n",
    "    - Which predictive biomarkers exist for the target related to the disease?\n",
    "        - Provide a detailed description of existing clinical relevant biomarkers.\n",
    "\n",
    "    - Clinical target rationale:\n",
    "    - How relevant is the target location to the disease biology?\n",
    "    - How it the target expression altered in human disease?\n",
    "    - How is the target involved in the physiological process relevant to the disease?\n",
    "    - Which phenotypes and genotypes were identified for the target?\n",
    "    - How is the genetic link between the target and the disease?\n",
    "    - Describe the evidence provided in clinics or by tools acting on the pathway where the target is involved.\n",
    "    - Which kind of target modulation is required to treat the disease?\n",
    "\n",
    "    - Challenges for the drug discovery program related to the target.\n",
    "    - Check the following idea for details on small molecule compounds: Develop an inhibitor of the neurokinin 3 receptor (NK3R) GPCR for the treatment of vasomotor symptoms due to menopause..\n",
    "    - Is a 'information driven approach' (IDA) strategy based on available small molecules possible?\n",
    "        - Which small molecular modulators of the target known?\n",
    "        - Which inhibitors, antagonists, agonists, negative allosteric modulators (NAM), positive allosteric modulators (PAM) are required for target modulation in the given disease? \n",
    "    - Which patients would respond the therapy?\n",
    "    - Is the proposed mode of action on the target desirable and commercially viable in a clinical setting?\n",
    "    - What are advantages and disadvantages of different therapeutic modalities (antibodies, small molecules, antisense oligonucleotides, PROTACs, molecular glue, peptide macrocycles, and so on) for tackling the target?\n",
    "\n",
    "    - Alternative indications:\n",
    "    - Describe alternative indication for modulators of the target and explain why.\"\"\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "refine_prompt ='''\n",
    "Referencing the answers provided by all agents, synthesize a more detailed and comprehensive response by integrating all relevant details from these answers. Ensure logical coherence and provide ONLY THE MERGED ANSWER AS THE OUTPUT, omitting any discussion of the comparison process or analytical thoughts.\n",
    "'''"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "num_agents = 3\n",
    "num_steps = 3\n",
    "final_output_mode = 'only_last_step'"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "async def pubmed_paperqa(query: str) -> str:\n",
    "    max_results: int = 10\n",
    "    pubmed_query = query\n",
    "    doc_query = query\n",
    "    email = \"sanazkazemi@hotmail.com\"\n",
    "    print(f\"pubmed_paperqa called with query: {query}, max_results: {max_results}\")\n",
    "    pubmed_instance = PubMedProcessor(email)\n",
    "    results_dict = await asyncio.to_thread(pubmed_instance.full_process, pubmed_query, doc_query, max_results)\n",
    "    return json.dumps(results_dict, indent=4)\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [],
   "source": [
    "def get_query(question, system_prompt, num_agents=3):\n",
    "\n",
    "    \"\"\"gets the queries from the user and returns n drafts of the agents\"\"\"\n",
    "    query_prompt = question\n",
    "    agents_draft = []\n",
    "\n",
    "\n",
    "    for i in range(num_agents):\n",
    "        draft = openai.chat.completions.create(\n",
    "            model=\"gpt-4o-mini\",\n",
    "            messages=[\n",
    "                {\n",
    "                    \"role\": \"system\",\n",
    "                    \"content\": system_prompt\n",
    "                },\n",
    "                {\n",
    "                    \"role\": \"user\",\n",
    "                    \"content\": query_prompt\n",
    "                }\n",
    "            ],\n",
    "            temperature=0.2\n",
    "        ).choices[0].message.content\n",
    "        agents_draft.append(draft)\n",
    "\n",
    "        print(f\"Agent {i+1} draft: {draft}\")\n",
    "\n",
    "    return agents_draft"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [],
   "source": [
    "scientific_rationale_system_prompt = \"\"\"You are 'scientific rationale', an expert in target discovery and assessment at a pharmaceutical company, you get commission when you assess and discovery a new target. \n",
    "                        You provide scientific rationales to support the selection of drug targets for a specific disease.\n",
    "                        You are meticulous in your analysis and provide evidence-based assessments to guide drug discovery efforts.\n",
    "                        Your role is to:\n",
    "                        1. Your primary role is to develop comprehensive scientific rationales for given targets in specified diseases using available literature. \"\"\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Agent 1 draft: **Working hypothesis:**\n",
      "\n",
      "The working hypothesis for targeting gamma-secretase (GSEC) in Alzheimer's disease (AD) is that the inhibition of GSEC will reduce the production of amyloid-beta (Aβ) peptides, particularly the aggregation-prone forms such as Aβ42 and Aβ43, thereby mitigating the formation of amyloid plaques, a hallmark of AD pathology. Given that the accumulation of these peptides is closely linked to neurodegeneration and cognitive decline, targeting GSEC could potentially slow disease progression and improve cognitive function in affected individuals.\n",
      "\n",
      "**Unmet medical need:**\n",
      "\n",
      "Alzheimer's disease represents a significant unmet medical need, as it is the most common form of dementia, affecting millions worldwide. Current therapeutic options are limited and primarily focus on symptomatic relief rather than addressing the underlying disease mechanisms. The need for disease-modifying therapies that can effectively halt or reverse the progression of AD is critical, particularly as the aging population continues to grow.\n",
      "\n",
      "**Suitability for combination therapy:**\n",
      "\n",
      "Given the multifactorial nature of Alzheimer's disease, targeting GSEC may be suitable for combination therapy with other agents that address different aspects of the disease, such as tau pathology, neuroinflammation, or synaptic dysfunction. This approach could enhance overall therapeutic efficacy and provide a more comprehensive treatment strategy.\n",
      "\n",
      "**Predictive biomarkers:**\n",
      "\n",
      "Several predictive biomarkers exist for Alzheimer's disease that are relevant to the gamma-secretase pathway. These include:\n",
      "\n",
      "1. **Amyloid PET Imaging:** Positron emission tomography (PET) imaging with amyloid tracers can visualize amyloid plaque burden in the brain, providing a direct measure of Aβ accumulation.\n",
      "   \n",
      "2. **Cerebrospinal Fluid (CSF) Aβ Levels:** Measurement of Aβ42 and Aβ40 in CSF can indicate the presence of amyloid pathology. A lower Aβ42/Aβ40 ratio is often associated with AD.\n",
      "\n",
      "3. **Neurodegeneration Biomarkers:** Levels of tau protein and neurofilament light chain (NfL) in CSF or blood can serve as indicators of neurodegeneration and correlate with cognitive decline.\n",
      "\n",
      "4. **Genetic Risk Factors:** Genetic variants in genes such as APOE (specifically the ε4 allele) are associated with increased risk for AD and can serve as predictive biomarkers for disease susceptibility.\n",
      "\n",
      "**Clinical target rationale:**\n",
      "\n",
      "1. **Relevance of target location to disease biology:** Gamma-secretase is located in the membrane of neurons and is crucial for the processing of APP, leading to the generation of Aβ peptides. Its role in Aβ production makes it highly relevant to the pathogenesis of Alzheimer's disease.\n",
      "\n",
      "2. **Altered target expression in human disease:** Studies have shown that the expression and activity of gamma-secretase components, particularly presenilins (PS1 and PS2), are altered in AD brains. Mutations in presenilin genes are linked to familial forms of AD, further implicating GSEC in disease pathology.\n",
      "\n",
      "3. **Involvement in physiological processes:** Gamma-secretase is involved in the cleavage of several type I transmembrane proteins, influencing various signaling pathways. Its dysregulation in APP processing leads to an imbalance in Aβ production, contributing to amyloid plaque formation and neurotoxicity.\n",
      "\n",
      "4. **Phenotypes and genotypes identified for the target:** Genetic studies have identified mutations in the presenilin genes that lead to increased production of pathogenic Aβ forms. These mutations result in early-onset familial Alzheimer's disease, highlighting the direct link between GSEC activity and disease phenotype.\n",
      "\n",
      "5. **Genetic link between the target and disease:** The presence of mutations in presenilin genes in familial AD cases provides strong genetic evidence linking gamma-secretase to the disease. Additionally, polymorphisms in genes related to the Aβ pathway may influence sporadic AD risk.\n",
      "\n",
      "6. **Evidence from clinical tools:** Clinical trials targeting GSEC have shown that modulation of Aβ levels can impact cognitive outcomes. For instance, the use of GSEC inhibitors has demonstrated a reduction in Aβ levels in CSF and brain tissue, correlating with improvements in cognitive function in some studies.\n",
      "\n",
      "7. **Required target modulation:** To treat Alzheimer's disease effectively, a balanced modulation of gamma-secretase activity is required. Complete inhibition may lead to adverse effects due to the essential role of GSEC in processing other substrates. Therefore, selective modulation that reduces Aβ production while preserving normal physiological functions is desirable.\n",
      "\n",
      "**Challenges for the drug discovery program:**\n",
      "\n",
      "1. **Selectivity and safety:** Developing selective GSEC inhibitors that do not disrupt the cleavage of other important substrates is a significant challenge. Non-selective inhibition could lead to unwanted side effects.\n",
      "\n",
      "2. **Complexity of the Aβ pathway:** The Aβ production pathway is complex, with multiple enzymes involved. Understanding the interplay between GSEC and other secretases (e.g., BACE) is crucial for effective target modulation.\n",
      "\n",
      "3. **Patient heterogeneity:** Alzheimer's disease is a heterogeneous condition, and responses to GSEC modulation may vary among patients based on genetic and phenotypic differences.\n",
      "\n",
      "4. **Regulatory hurdles:** The approval process for new therapies targeting the amyloid pathway has been challenging, with recent setbacks highlighting the need for robust clinical evidence of efficacy.\n",
      "\n",
      "**Information-driven approach (IDA) strategy:**\n",
      "\n",
      "1. **Known small molecular modulators:** Several small molecule inhibitors of gamma-secretase have been developed, including semagacestat and avagacestat. However, these compounds have faced challenges in clinical trials due to adverse effects and lack of efficacy.\n",
      "\n",
      "2. **Required modulators:** For effective target modulation, a combination of inhibitors and selective modulators may be necessary. Positive allosteric modulators (PAMs) could enhance the desired effects of GSEC inhibition while minimizing side effects.\n",
      "\n",
      "3. **Patient response:** Patients with specific genetic profiles, such as those with familial AD mutations in presenilin genes, may respond more favorably to GSEC modulation. Additionally, individuals with elevated amyloid levels may be more likely to benefit from therapies targeting this pathway.\n",
      "\n",
      "4. **Commercial viability:** The proposed mode of action targeting GSEC is commercially viable, given the high unmet need in Alzheimer's disease. Successful modulation of Aβ production could lead to significant market opportunities.\n",
      "\n",
      "5. **Therapeutic modalities:** Different therapeutic modalities present various advantages and disadvantages. For example:\n",
      "   - **Antibodies:** High specificity for Aβ but may require parenteral administration.\n",
      "   - **Small molecules:** Oral bioavailability but may face challenges with selectivity.\n",
      "   - **Antisense oligonucleotides:** Target specific mRNA but may have delivery challenges.\n",
      "   - **PROTACs:** Offer targeted degradation of proteins but are still in early development stages.\n",
      "\n",
      "**Alternative indications:**\n",
      "\n",
      "Modulators of gamma-secretase may have potential in other neurodegenerative diseases characterized by protein aggregation, such as frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). In these conditions, the dysregulation of protein processing pathways may contribute to disease pathology, making GSEC a relevant target for exploration in these alternative indications. Additionally, targeting GSEC could have implications in other diseases where Aβ-like peptides are involved, such as type 2 diabetes, where amyloid deposits are observed in pancreatic islets.\n",
      "Agent 2 draft: **Working hypothesis:**\n",
      "\n",
      "The working hypothesis for targeting gamma secretase (GSEC) in Alzheimer's disease (AD) is that the inhibition of GSEC will reduce the production of amyloid-beta (Aβ) peptides, particularly the aggregation-prone forms such as Aβ42 and Aβ43, thereby mitigating the formation of amyloid plaques, which are a hallmark of AD pathology. This hypothesis is supported by the understanding that GSEC plays a critical role in the cleavage of the amyloid precursor protein (APP), leading to the generation of Aβ peptides. By modulating GSEC activity, it may be possible to alter the course of AD and improve cognitive outcomes in affected individuals.\n",
      "\n",
      "**Unmet medical need:**\n",
      "\n",
      "Alzheimer's disease represents a significant unmet medical need, as it is the most common form of dementia, affecting millions of individuals worldwide. Current therapeutic options are limited and primarily focus on symptomatic relief rather than addressing the underlying disease mechanisms. The progressive nature of AD leads to severe cognitive decline and loss of independence, highlighting the urgent need for disease-modifying therapies that can effectively target the pathophysiological processes involved in AD, particularly the accumulation of amyloid plaques.\n",
      "\n",
      "**Combination therapy suitability:**\n",
      "\n",
      "Given the multifactorial nature of Alzheimer's disease, targeting GSEC may be suitable for combination therapy with other agents that address different aspects of the disease, such as tau pathology or neuroinflammation. Combining GSEC inhibitors with other therapeutic modalities could enhance overall efficacy and provide a more comprehensive approach to treatment.\n",
      "\n",
      "**Predictive biomarkers:**\n",
      "\n",
      "Several predictive biomarkers exist that are relevant to the target and the pathogenesis of Alzheimer's disease. These include:\n",
      "\n",
      "1. **Amyloid PET Imaging:** Positron emission tomography (PET) imaging using amyloid tracers (e.g., [11C]PiB) can visualize amyloid plaque deposition in the brain, providing a direct measure of the pathological hallmark of AD.\n",
      "\n",
      "2. **Cerebrospinal Fluid (CSF) Biomarkers:** The levels of Aβ42, total tau, and phosphorylated tau in CSF are established biomarkers for AD. A decrease in Aβ42 levels, along with an increase in tau levels, is indicative of AD pathology.\n",
      "\n",
      "3. **Genetic Biomarkers:** Variants in genes such as APOE (particularly the ε4 allele) are associated with an increased risk of developing AD and can serve as predictive biomarkers for disease susceptibility.\n",
      "\n",
      "**Clinical target rationale:**\n",
      "\n",
      "1. **Target location relevance:** Gamma secretase is located in the membrane of neurons and glial cells, where it cleaves APP and other substrates. Its localization is highly relevant to the pathogenesis of AD, as the generation of Aβ occurs at the synaptic level, influencing neuronal health and function.\n",
      "\n",
      "2. **Altered target expression:** Studies have shown that the expression of gamma secretase components, particularly presenilins (PS1 and PS2), is altered in AD brains. Mutations in presenilin genes are linked to familial forms of AD, underscoring the importance of GSEC in the disease.\n",
      "\n",
      "3. **Physiological involvement:** Gamma secretase is involved in the physiological processing of various type I transmembrane proteins, including Notch, which plays a role in cell signaling and neurogenesis. Dysregulation of GSEC can lead to both increased Aβ production and impaired Notch signaling, contributing to neurodegeneration.\n",
      "\n",
      "4. **Phenotypes and genotypes:** Genetic studies have identified several mutations in the APP and presenilin genes that lead to increased Aβ production and early-onset familial AD. These genetic links provide strong evidence for the role of GSEC in AD pathogenesis.\n",
      "\n",
      "5. **Clinical evidence:** Clinical trials targeting GSEC have shown mixed results, with some inhibitors demonstrating a reduction in Aβ levels in CSF and brain tissue. However, the challenge remains to achieve a balance between reducing Aβ production and maintaining the physiological functions of GSEC.\n",
      "\n",
      "6. **Target modulation requirements:** Effective treatment of AD may require partial inhibition of GSEC to reduce Aβ production while preserving its function in processing other substrates. This necessitates a careful modulation strategy to avoid adverse effects.\n",
      "\n",
      "**Challenges for the drug discovery program:**\n",
      "\n",
      "1. **Selectivity and specificity:** Developing GSEC inhibitors that selectively target Aβ production without affecting other critical pathways regulated by GSEC, such as Notch signaling, poses a significant challenge.\n",
      "\n",
      "2. **Safety and tolerability:** Inhibition of GSEC may lead to unintended consequences, including potential neurotoxicity or disruption of normal cellular processes, necessitating thorough safety evaluations in clinical trials.\n",
      "\n",
      "3. **Patient heterogeneity:** Alzheimer's disease is a heterogeneous condition, and individual patient responses to GSEC modulation may vary based on genetic and environmental factors.\n",
      "\n",
      "**Information-driven approach (IDA):**\n",
      "\n",
      "1. **Known small molecular modulators:** Several small molecule inhibitors of GSEC have been developed, including compounds like semagacestat and avagacestat. However, these have faced challenges in clinical trials due to adverse effects.\n",
      "\n",
      "2. **Required modulators:** A combination of inhibitors, antagonists, and possibly positive allosteric modulators may be required to achieve the desired modulation of GSEC activity while minimizing side effects.\n",
      "\n",
      "3. **Patient response:** Patients with early-stage AD or those with specific genetic risk factors (e.g., APOE ε4 carriers) may be more likely to respond to GSEC-targeted therapies.\n",
      "\n",
      "4. **Commercial viability:** The proposed mode of action targeting GSEC is commercially viable, given the significant market potential for effective AD therapies. However, the competitive landscape and regulatory hurdles must be considered.\n",
      "\n",
      "5. **Therapeutic modalities:** Different therapeutic modalities present various advantages and disadvantages. Small molecules may offer oral bioavailability and ease of administration, while monoclonal antibodies may provide higher specificity but require intravenous administration. Antisense oligonucleotides could offer a novel approach to modulate gene expression, but delivery to the central nervous system remains a challenge.\n",
      "\n",
      "**Alternative indications:**\n",
      "\n",
      "Modulators of gamma secretase may have potential in other neurodegenerative diseases characterized by protein aggregation, such as frontotemporal dementia (FTD) or amyotrophic lateral sclerosis (ALS). The commonality of protein misfolding and aggregation in these conditions suggests that GSEC modulation could be beneficial in reducing toxic protein species and improving neuronal health. Additionally, targeting GSEC may have implications in cancer biology, where Notch signaling plays a critical role in tumorigenesis, presenting an opportunity for dual-targeting strategies in oncology.\n",
      "Agent 3 draft: **Working hypothesis:**\n",
      "\n",
      "The working hypothesis for targeting gamma-secretase (GSEC) in Alzheimer's disease (AD) is that modulation of this multi-subunit protease complex can effectively reduce the production of amyloid-beta (Aβ) peptides, particularly the aggregation-prone forms such as Aβ42 and Aβ43, thereby mitigating the formation of amyloid plaques that are characteristic of AD pathology. The hypothesis posits that by inhibiting GSEC activity, the downstream effects of Aβ aggregation, neuroinflammation, and neuronal toxicity can be alleviated, leading to improved cognitive function and a potential slowing of disease progression.\n",
      "\n",
      "**Unmet medical need:**\n",
      "\n",
      "Alzheimer's disease represents a significant unmet medical need, with millions of individuals affected globally. Current therapeutic options are limited and primarily focus on symptomatic relief rather than addressing the underlying pathophysiology. The need for disease-modifying therapies that can effectively target the amyloid cascade hypothesis remains critical, as existing treatments do not halt or reverse the cognitive decline associated with AD. The development of GSEC inhibitors could fulfill this need by directly targeting the source of Aβ production.\n",
      "\n",
      "**Suitability for combination therapy:**\n",
      "\n",
      "Given the multifactorial nature of Alzheimer's disease, GSEC inhibitors may be suitable for combination therapy with other modalities targeting different aspects of the disease, such as tau pathology, neuroinflammation, or cholinergic deficits. Combining GSEC inhibition with agents that enhance synaptic function or reduce neuroinflammation could provide a synergistic effect, potentially leading to better clinical outcomes.\n",
      "\n",
      "**Predictive biomarkers:**\n",
      "\n",
      "Several predictive biomarkers exist that are relevant to the modulation of gamma-secretase in Alzheimer's disease. These include:\n",
      "\n",
      "1. **Amyloid PET Imaging:** Positron emission tomography (PET) imaging with amyloid tracers (e.g., [11C]PiB) can visualize amyloid plaque burden in the brain, providing a direct measure of Aβ accumulation.\n",
      "\n",
      "2. **Cerebrospinal Fluid (CSF) Aβ Levels:** Measurement of Aβ42 and Aβ40 levels in CSF can serve as a biomarker for GSEC activity, as alterations in these levels reflect changes in amyloid processing.\n",
      "\n",
      "3. **Neurodegeneration Biomarkers:** Levels of neurodegeneration markers such as total tau (t-tau) and phosphorylated tau (p-tau) in CSF can indicate the downstream effects of Aβ accumulation and neuronal damage.\n",
      "\n",
      "4. **Genetic Risk Factors:** Genetic variants in genes related to amyloid processing, such as APOE ε4 allele, can serve as predictive biomarkers for disease risk and progression.\n",
      "\n",
      "**Clinical target rationale:**\n",
      "\n",
      "1. **Target location relevance:** Gamma-secretase is located in the membrane of neurons and glial cells, where it plays a crucial role in the processing of APP and the generation of Aβ peptides. Its localization is directly relevant to the pathogenesis of Alzheimer's disease, as the accumulation of Aβ in the brain is a hallmark of the disease.\n",
      "\n",
      "2. **Altered target expression:** Studies have shown that the expression levels of gamma-secretase components, particularly presenilins (PS1 and PS2), are altered in the brains of AD patients. Increased activity of GSEC has been associated with higher levels of toxic Aβ42, indicating a direct link between target expression and disease pathology.\n",
      "\n",
      "3. **Physiological process involvement:** Gamma-secretase is involved in the cleavage of various type I transmembrane proteins beyond APP, including Notch receptors, which are essential for cell signaling and neuronal health. Dysregulation of GSEC can lead to both increased Aβ production and impaired Notch signaling, contributing to neurodegeneration.\n",
      "\n",
      "4. **Phenotypes and genotypes:** Genetic mutations in presenilin genes (PSEN1 and PSEN2) are known to cause familial forms of Alzheimer's disease, leading to early-onset AD. These mutations often result in altered GSEC activity, producing a higher ratio of Aβ42 to Aβ40, which is associated with increased amyloid plaque formation.\n",
      "\n",
      "5. **Genetic link evidence:** The genetic association between GSEC and Alzheimer's disease is well-established, with numerous studies linking mutations in presenilin genes to familial AD. Additionally, polymorphisms in genes related to Aβ metabolism have been implicated in sporadic AD cases.\n",
      "\n",
      "6. **Clinical evidence:** Clinical trials targeting GSEC have shown that modulation of Aβ levels can influence cognitive outcomes. For instance, GSEC inhibitors have demonstrated the ability to lower Aβ levels in CSF and reduce amyloid plaque burden in preclinical models, providing a rationale for their potential efficacy in humans.\n",
      "\n",
      "7. **Target modulation requirements:** To effectively treat Alzheimer's disease, a balanced modulation of gamma-secretase is required. Complete inhibition may lead to adverse effects due to the essential role of GSEC in processing other substrates, such as Notch. Therefore, selective inhibitors that preferentially reduce Aβ production while preserving normal GSEC function are desirable.\n",
      "\n",
      "**Challenges for the drug discovery program:**\n",
      "\n",
      "1. **Selectivity and safety:** Developing selective GSEC inhibitors that do not disrupt the processing of other critical substrates poses a significant challenge. Inhibition of Notch signaling can lead to unwanted side effects, including impaired neurogenesis and cognitive function.\n",
      "\n",
      "2. **Heterogeneity of Alzheimer's disease:** The variability in disease pathology among patients complicates the identification of a one-size-fits-all therapeutic approach. Personalized medicine strategies may be necessary to optimize treatment based on individual patient profiles.\n",
      "\n",
      "3. **Clinical trial design:** Designing clinical trials that adequately assess the efficacy of GSEC inhibitors in a heterogeneous patient population while accounting for the multifactorial nature of AD is complex.\n",
      "\n",
      "4. **Regulatory hurdles:** Gaining regulatory approval for new therapies targeting the amyloid pathway has been challenging, as seen with recent controversies surrounding amyloid-targeting drugs.\n",
      "\n",
      "**Information-driven approach (IDA) strategy:**\n",
      "\n",
      "1. **Small molecular modulators:** Several small molecule modulators of gamma-secretase have been identified, including compounds that selectively inhibit the production of Aβ42 while sparing Aβ40. Examples include semagacestat and avagacestat, although they faced challenges in clinical development.\n",
      "\n",
      "2. **Required modulators:** For effective target modulation, a combination of inhibitors and selective modulators may be required. Negative allosteric modulators (NAMs) that reduce GSEC activity without complete inhibition could be explored, as well as positive allosteric modulators (PAMs) that enhance the processing of non-amyloidogenic pathways.\n",
      "\n",
      "3. **Patient response:** Patients with elevated levels of Aβ42 or those with genetic predispositions to AD may be more likely to respond to GSEC-targeted therapies. Biomarker-driven patient selection could enhance the likelihood of therapeutic success.\n",
      "\n",
      "4. **Commercial viability:** The proposed mode of action targeting GSEC is commercially viable, given the high unmet need in Alzheimer's disease. Successful modulation of Aβ production could lead to significant market opportunities, especially if combined with other therapeutic strategies.\n",
      "\n",
      "5. **Therapeutic modalities:** Different therapeutic modalities present advantages and disadvantages. Antibodies targeting Aβ may provide high specificity but require parenteral administration. Small molecules offer oral bioavailability but may face challenges with selectivity. Antisense oligonucleotides could provide a novel approach to modulate gene expression but require careful delivery mechanisms. PROTACs and molecular glues represent innovative strategies for targeted degradation of GSEC components but are still in early stages of development.\n",
      "\n",
      "**Alternative indications:**\n",
      "\n",
      "Modulators of gamma-secretase may have alternative indications beyond Alzheimer's disease. Potential areas include:\n",
      "\n",
      "1. **Frontotemporal dementia (FTD):** Certain forms of FTD are associated with abnormal protein aggregation, including tau and TDP-43. Targeting GSEC may help modulate pathways involved in these aggregates.\n",
      "\n",
      "2. **Cognitive impairment in Down syndrome:** Individuals with Down syndrome have an increased risk of developing Alzheimer's-like pathology due to triplication of the APP gene. GSEC inhibitors could potentially mitigate cognitive decline in this population.\n",
      "\n",
      "3. **Other neurodegenerative diseases:** Given the role of Aβ in neuroinflammation and neuronal toxicity, GSEC modulation may have therapeutic potential in other neurodegenerative diseases characterized by protein aggregation, such as Parkinson's disease or Huntington's disease.\n",
      "\n",
      "In conclusion, targeting gamma-secretase presents a compelling strategy for addressing the underlying pathology of Alzheimer's disease. The scientific rationale is supported by extensive evidence linking GSEC activity to Aβ production and subsequent neurodegeneration. Continued research and development efforts are essential to overcome the challenges associated with this target and to realize its potential in improving outcomes for patients with Alzheimer's disease and related disorders.\n"
     ]
    }
   ],
   "source": [
    "step_1 = get_query(question=chatgpt_system_prompt, system_prompt=scientific_rationale_system_prompt, num_agents=3)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Step 1:  [\"**Working hypothesis:**\\n\\nThe working hypothesis for targeting gamma-secretase (GSEC) in Alzheimer's disease (AD) is that the inhibition of GSEC will reduce the production of amyloid-beta (Aβ) peptides, particularly the aggregation-prone forms such as Aβ42 and Aβ43, thereby mitigating the formation of amyloid plaques, a hallmark of AD pathology. Given that the accumulation of these peptides is closely linked to neurodegeneration and cognitive decline, targeting GSEC could potentially slow disease progression and improve cognitive function in affected individuals.\\n\\n**Unmet medical need:**\\n\\nAlzheimer's disease represents a significant unmet medical need, as it is the most common form of dementia, affecting millions worldwide. Current therapeutic options are limited and primarily focus on symptomatic relief rather than addressing the underlying disease mechanisms. The need for disease-modifying therapies that can effectively halt or reverse the progression of AD is critical, particularly as the aging population continues to grow.\\n\\n**Suitability for combination therapy:**\\n\\nGiven the multifactorial nature of Alzheimer's disease, targeting GSEC may be suitable for combination therapy with other agents that address different aspects of the disease, such as tau pathology, neuroinflammation, or synaptic dysfunction. This approach could enhance overall therapeutic efficacy and provide a more comprehensive treatment strategy.\\n\\n**Predictive biomarkers:**\\n\\nSeveral predictive biomarkers exist for Alzheimer's disease that are relevant to the gamma-secretase pathway. These include:\\n\\n1. **Amyloid PET Imaging:** Positron emission tomography (PET) imaging with amyloid tracers can visualize amyloid plaque burden in the brain, providing a direct measure of Aβ accumulation.\\n   \\n2. **Cerebrospinal Fluid (CSF) Aβ Levels:** Measurement of Aβ42 and Aβ40 in CSF can indicate the presence of amyloid pathology. A lower Aβ42/Aβ40 ratio is often associated with AD.\\n\\n3. **Neurodegeneration Biomarkers:** Levels of tau protein and neurofilament light chain (NfL) in CSF or blood can serve as indicators of neurodegeneration and correlate with cognitive decline.\\n\\n4. **Genetic Risk Factors:** Genetic variants in genes such as APOE (specifically the ε4 allele) are associated with increased risk for AD and can serve as predictive biomarkers for disease susceptibility.\\n\\n**Clinical target rationale:**\\n\\n1. **Relevance of target location to disease biology:** Gamma-secretase is located in the membrane of neurons and is crucial for the processing of APP, leading to the generation of Aβ peptides. Its role in Aβ production makes it highly relevant to the pathogenesis of Alzheimer's disease.\\n\\n2. **Altered target expression in human disease:** Studies have shown that the expression and activity of gamma-secretase components, particularly presenilins (PS1 and PS2), are altered in AD brains. Mutations in presenilin genes are linked to familial forms of AD, further implicating GSEC in disease pathology.\\n\\n3. **Involvement in physiological processes:** Gamma-secretase is involved in the cleavage of several type I transmembrane proteins, influencing various signaling pathways. Its dysregulation in APP processing leads to an imbalance in Aβ production, contributing to amyloid plaque formation and neurotoxicity.\\n\\n4. **Phenotypes and genotypes identified for the target:** Genetic studies have identified mutations in the presenilin genes that lead to increased production of pathogenic Aβ forms. These mutations result in early-onset familial Alzheimer's disease, highlighting the direct link between GSEC activity and disease phenotype.\\n\\n5. **Genetic link between the target and disease:** The presence of mutations in presenilin genes in familial AD cases provides strong genetic evidence linking gamma-secretase to the disease. Additionally, polymorphisms in genes related to the Aβ pathway may influence sporadic AD risk.\\n\\n6. **Evidence from clinical tools:** Clinical trials targeting GSEC have shown that modulation of Aβ levels can impact cognitive outcomes. For instance, the use of GSEC inhibitors has demonstrated a reduction in Aβ levels in CSF and brain tissue, correlating with improvements in cognitive function in some studies.\\n\\n7. **Required target modulation:** To treat Alzheimer's disease effectively, a balanced modulation of gamma-secretase activity is required. Complete inhibition may lead to adverse effects due to the essential role of GSEC in processing other substrates. Therefore, selective modulation that reduces Aβ production while preserving normal physiological functions is desirable.\\n\\n**Challenges for the drug discovery program:**\\n\\n1. **Selectivity and safety:** Developing selective GSEC inhibitors that do not disrupt the cleavage of other important substrates is a significant challenge. Non-selective inhibition could lead to unwanted side effects.\\n\\n2. **Complexity of the Aβ pathway:** The Aβ production pathway is complex, with multiple enzymes involved. Understanding the interplay between GSEC and other secretases (e.g., BACE) is crucial for effective target modulation.\\n\\n3. **Patient heterogeneity:** Alzheimer's disease is a heterogeneous condition, and responses to GSEC modulation may vary among patients based on genetic and phenotypic differences.\\n\\n4. **Regulatory hurdles:** The approval process for new therapies targeting the amyloid pathway has been challenging, with recent setbacks highlighting the need for robust clinical evidence of efficacy.\\n\\n**Information-driven approach (IDA) strategy:**\\n\\n1. **Known small molecular modulators:** Several small molecule inhibitors of gamma-secretase have been developed, including semagacestat and avagacestat. However, these compounds have faced challenges in clinical trials due to adverse effects and lack of efficacy.\\n\\n2. **Required modulators:** For effective target modulation, a combination of inhibitors and selective modulators may be necessary. Positive allosteric modulators (PAMs) could enhance the desired effects of GSEC inhibition while minimizing side effects.\\n\\n3. **Patient response:** Patients with specific genetic profiles, such as those with familial AD mutations in presenilin genes, may respond more favorably to GSEC modulation. Additionally, individuals with elevated amyloid levels may be more likely to benefit from therapies targeting this pathway.\\n\\n4. **Commercial viability:** The proposed mode of action targeting GSEC is commercially viable, given the high unmet need in Alzheimer's disease. Successful modulation of Aβ production could lead to significant market opportunities.\\n\\n5. **Therapeutic modalities:** Different therapeutic modalities present various advantages and disadvantages. For example:\\n   - **Antibodies:** High specificity for Aβ but may require parenteral administration.\\n   - **Small molecules:** Oral bioavailability but may face challenges with selectivity.\\n   - **Antisense oligonucleotides:** Target specific mRNA but may have delivery challenges.\\n   - **PROTACs:** Offer targeted degradation of proteins but are still in early development stages.\\n\\n**Alternative indications:**\\n\\nModulators of gamma-secretase may have potential in other neurodegenerative diseases characterized by protein aggregation, such as frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). In these conditions, the dysregulation of protein processing pathways may contribute to disease pathology, making GSEC a relevant target for exploration in these alternative indications. Additionally, targeting GSEC could have implications in other diseases where Aβ-like peptides are involved, such as type 2 diabetes, where amyloid deposits are observed in pancreatic islets.\", \"**Working hypothesis:**\\n\\nThe working hypothesis for targeting gamma secretase (GSEC) in Alzheimer's disease (AD) is that the inhibition of GSEC will reduce the production of amyloid-beta (Aβ) peptides, particularly the aggregation-prone forms such as Aβ42 and Aβ43, thereby mitigating the formation of amyloid plaques, which are a hallmark of AD pathology. This hypothesis is supported by the understanding that GSEC plays a critical role in the cleavage of the amyloid precursor protein (APP), leading to the generation of Aβ peptides. By modulating GSEC activity, it may be possible to alter the course of AD and improve cognitive outcomes in affected individuals.\\n\\n**Unmet medical need:**\\n\\nAlzheimer's disease represents a significant unmet medical need, as it is the most common form of dementia, affecting millions of individuals worldwide. Current therapeutic options are limited and primarily focus on symptomatic relief rather than addressing the underlying disease mechanisms. The progressive nature of AD leads to severe cognitive decline and loss of independence, highlighting the urgent need for disease-modifying therapies that can effectively target the pathophysiological processes involved in AD, particularly the accumulation of amyloid plaques.\\n\\n**Combination therapy suitability:**\\n\\nGiven the multifactorial nature of Alzheimer's disease, targeting GSEC may be suitable for combination therapy with other agents that address different aspects of the disease, such as tau pathology or neuroinflammation. Combining GSEC inhibitors with other therapeutic modalities could enhance overall efficacy and provide a more comprehensive approach to treatment.\\n\\n**Predictive biomarkers:**\\n\\nSeveral predictive biomarkers exist that are relevant to the target and the pathogenesis of Alzheimer's disease. These include:\\n\\n1. **Amyloid PET Imaging:** Positron emission tomography (PET) imaging using amyloid tracers (e.g., [11C]PiB) can visualize amyloid plaque deposition in the brain, providing a direct measure of the pathological hallmark of AD.\\n\\n2. **Cerebrospinal Fluid (CSF) Biomarkers:** The levels of Aβ42, total tau, and phosphorylated tau in CSF are established biomarkers for AD. A decrease in Aβ42 levels, along with an increase in tau levels, is indicative of AD pathology.\\n\\n3. **Genetic Biomarkers:** Variants in genes such as APOE (particularly the ε4 allele) are associated with an increased risk of developing AD and can serve as predictive biomarkers for disease susceptibility.\\n\\n**Clinical target rationale:**\\n\\n1. **Target location relevance:** Gamma secretase is located in the membrane of neurons and glial cells, where it cleaves APP and other substrates. Its localization is highly relevant to the pathogenesis of AD, as the generation of Aβ occurs at the synaptic level, influencing neuronal health and function.\\n\\n2. **Altered target expression:** Studies have shown that the expression of gamma secretase components, particularly presenilins (PS1 and PS2), is altered in AD brains. Mutations in presenilin genes are linked to familial forms of AD, underscoring the importance of GSEC in the disease.\\n\\n3. **Physiological involvement:** Gamma secretase is involved in the physiological processing of various type I transmembrane proteins, including Notch, which plays a role in cell signaling and neurogenesis. Dysregulation of GSEC can lead to both increased Aβ production and impaired Notch signaling, contributing to neurodegeneration.\\n\\n4. **Phenotypes and genotypes:** Genetic studies have identified several mutations in the APP and presenilin genes that lead to increased Aβ production and early-onset familial AD. These genetic links provide strong evidence for the role of GSEC in AD pathogenesis.\\n\\n5. **Clinical evidence:** Clinical trials targeting GSEC have shown mixed results, with some inhibitors demonstrating a reduction in Aβ levels in CSF and brain tissue. However, the challenge remains to achieve a balance between reducing Aβ production and maintaining the physiological functions of GSEC.\\n\\n6. **Target modulation requirements:** Effective treatment of AD may require partial inhibition of GSEC to reduce Aβ production while preserving its function in processing other substrates. This necessitates a careful modulation strategy to avoid adverse effects.\\n\\n**Challenges for the drug discovery program:**\\n\\n1. **Selectivity and specificity:** Developing GSEC inhibitors that selectively target Aβ production without affecting other critical pathways regulated by GSEC, such as Notch signaling, poses a significant challenge.\\n\\n2. **Safety and tolerability:** Inhibition of GSEC may lead to unintended consequences, including potential neurotoxicity or disruption of normal cellular processes, necessitating thorough safety evaluations in clinical trials.\\n\\n3. **Patient heterogeneity:** Alzheimer's disease is a heterogeneous condition, and individual patient responses to GSEC modulation may vary based on genetic and environmental factors.\\n\\n**Information-driven approach (IDA):**\\n\\n1. **Known small molecular modulators:** Several small molecule inhibitors of GSEC have been developed, including compounds like semagacestat and avagacestat. However, these have faced challenges in clinical trials due to adverse effects.\\n\\n2. **Required modulators:** A combination of inhibitors, antagonists, and possibly positive allosteric modulators may be required to achieve the desired modulation of GSEC activity while minimizing side effects.\\n\\n3. **Patient response:** Patients with early-stage AD or those with specific genetic risk factors (e.g., APOE ε4 carriers) may be more likely to respond to GSEC-targeted therapies.\\n\\n4. **Commercial viability:** The proposed mode of action targeting GSEC is commercially viable, given the significant market potential for effective AD therapies. However, the competitive landscape and regulatory hurdles must be considered.\\n\\n5. **Therapeutic modalities:** Different therapeutic modalities present various advantages and disadvantages. Small molecules may offer oral bioavailability and ease of administration, while monoclonal antibodies may provide higher specificity but require intravenous administration. Antisense oligonucleotides could offer a novel approach to modulate gene expression, but delivery to the central nervous system remains a challenge.\\n\\n**Alternative indications:**\\n\\nModulators of gamma secretase may have potential in other neurodegenerative diseases characterized by protein aggregation, such as frontotemporal dementia (FTD) or amyotrophic lateral sclerosis (ALS). The commonality of protein misfolding and aggregation in these conditions suggests that GSEC modulation could be beneficial in reducing toxic protein species and improving neuronal health. Additionally, targeting GSEC may have implications in cancer biology, where Notch signaling plays a critical role in tumorigenesis, presenting an opportunity for dual-targeting strategies in oncology.\", \"**Working hypothesis:**\\n\\nThe working hypothesis for targeting gamma-secretase (GSEC) in Alzheimer's disease (AD) is that modulation of this multi-subunit protease complex can effectively reduce the production of amyloid-beta (Aβ) peptides, particularly the aggregation-prone forms such as Aβ42 and Aβ43, thereby mitigating the formation of amyloid plaques that are characteristic of AD pathology. The hypothesis posits that by inhibiting GSEC activity, the downstream effects of Aβ aggregation, neuroinflammation, and neuronal toxicity can be alleviated, leading to improved cognitive function and a potential slowing of disease progression.\\n\\n**Unmet medical need:**\\n\\nAlzheimer's disease represents a significant unmet medical need, with millions of individuals affected globally. Current therapeutic options are limited and primarily focus on symptomatic relief rather than addressing the underlying pathophysiology. The need for disease-modifying therapies that can effectively target the amyloid cascade hypothesis remains critical, as existing treatments do not halt or reverse the cognitive decline associated with AD. The development of GSEC inhibitors could fulfill this need by directly targeting the source of Aβ production.\\n\\n**Suitability for combination therapy:**\\n\\nGiven the multifactorial nature of Alzheimer's disease, GSEC inhibitors may be suitable for combination therapy with other modalities targeting different aspects of the disease, such as tau pathology, neuroinflammation, or cholinergic deficits. Combining GSEC inhibition with agents that enhance synaptic function or reduce neuroinflammation could provide a synergistic effect, potentially leading to better clinical outcomes.\\n\\n**Predictive biomarkers:**\\n\\nSeveral predictive biomarkers exist that are relevant to the modulation of gamma-secretase in Alzheimer's disease. These include:\\n\\n1. **Amyloid PET Imaging:** Positron emission tomography (PET) imaging with amyloid tracers (e.g., [11C]PiB) can visualize amyloid plaque burden in the brain, providing a direct measure of Aβ accumulation.\\n\\n2. **Cerebrospinal Fluid (CSF) Aβ Levels:** Measurement of Aβ42 and Aβ40 levels in CSF can serve as a biomarker for GSEC activity, as alterations in these levels reflect changes in amyloid processing.\\n\\n3. **Neurodegeneration Biomarkers:** Levels of neurodegeneration markers such as total tau (t-tau) and phosphorylated tau (p-tau) in CSF can indicate the downstream effects of Aβ accumulation and neuronal damage.\\n\\n4. **Genetic Risk Factors:** Genetic variants in genes related to amyloid processing, such as APOE ε4 allele, can serve as predictive biomarkers for disease risk and progression.\\n\\n**Clinical target rationale:**\\n\\n1. **Target location relevance:** Gamma-secretase is located in the membrane of neurons and glial cells, where it plays a crucial role in the processing of APP and the generation of Aβ peptides. Its localization is directly relevant to the pathogenesis of Alzheimer's disease, as the accumulation of Aβ in the brain is a hallmark of the disease.\\n\\n2. **Altered target expression:** Studies have shown that the expression levels of gamma-secretase components, particularly presenilins (PS1 and PS2), are altered in the brains of AD patients. Increased activity of GSEC has been associated with higher levels of toxic Aβ42, indicating a direct link between target expression and disease pathology.\\n\\n3. **Physiological process involvement:** Gamma-secretase is involved in the cleavage of various type I transmembrane proteins beyond APP, including Notch receptors, which are essential for cell signaling and neuronal health. Dysregulation of GSEC can lead to both increased Aβ production and impaired Notch signaling, contributing to neurodegeneration.\\n\\n4. **Phenotypes and genotypes:** Genetic mutations in presenilin genes (PSEN1 and PSEN2) are known to cause familial forms of Alzheimer's disease, leading to early-onset AD. These mutations often result in altered GSEC activity, producing a higher ratio of Aβ42 to Aβ40, which is associated with increased amyloid plaque formation.\\n\\n5. **Genetic link evidence:** The genetic association between GSEC and Alzheimer's disease is well-established, with numerous studies linking mutations in presenilin genes to familial AD. Additionally, polymorphisms in genes related to Aβ metabolism have been implicated in sporadic AD cases.\\n\\n6. **Clinical evidence:** Clinical trials targeting GSEC have shown that modulation of Aβ levels can influence cognitive outcomes. For instance, GSEC inhibitors have demonstrated the ability to lower Aβ levels in CSF and reduce amyloid plaque burden in preclinical models, providing a rationale for their potential efficacy in humans.\\n\\n7. **Target modulation requirements:** To effectively treat Alzheimer's disease, a balanced modulation of gamma-secretase is required. Complete inhibition may lead to adverse effects due to the essential role of GSEC in processing other substrates, such as Notch. Therefore, selective inhibitors that preferentially reduce Aβ production while preserving normal GSEC function are desirable.\\n\\n**Challenges for the drug discovery program:**\\n\\n1. **Selectivity and safety:** Developing selective GSEC inhibitors that do not disrupt the processing of other critical substrates poses a significant challenge. Inhibition of Notch signaling can lead to unwanted side effects, including impaired neurogenesis and cognitive function.\\n\\n2. **Heterogeneity of Alzheimer's disease:** The variability in disease pathology among patients complicates the identification of a one-size-fits-all therapeutic approach. Personalized medicine strategies may be necessary to optimize treatment based on individual patient profiles.\\n\\n3. **Clinical trial design:** Designing clinical trials that adequately assess the efficacy of GSEC inhibitors in a heterogeneous patient population while accounting for the multifactorial nature of AD is complex.\\n\\n4. **Regulatory hurdles:** Gaining regulatory approval for new therapies targeting the amyloid pathway has been challenging, as seen with recent controversies surrounding amyloid-targeting drugs.\\n\\n**Information-driven approach (IDA) strategy:**\\n\\n1. **Small molecular modulators:** Several small molecule modulators of gamma-secretase have been identified, including compounds that selectively inhibit the production of Aβ42 while sparing Aβ40. Examples include semagacestat and avagacestat, although they faced challenges in clinical development.\\n\\n2. **Required modulators:** For effective target modulation, a combination of inhibitors and selective modulators may be required. Negative allosteric modulators (NAMs) that reduce GSEC activity without complete inhibition could be explored, as well as positive allosteric modulators (PAMs) that enhance the processing of non-amyloidogenic pathways.\\n\\n3. **Patient response:** Patients with elevated levels of Aβ42 or those with genetic predispositions to AD may be more likely to respond to GSEC-targeted therapies. Biomarker-driven patient selection could enhance the likelihood of therapeutic success.\\n\\n4. **Commercial viability:** The proposed mode of action targeting GSEC is commercially viable, given the high unmet need in Alzheimer's disease. Successful modulation of Aβ production could lead to significant market opportunities, especially if combined with other therapeutic strategies.\\n\\n5. **Therapeutic modalities:** Different therapeutic modalities present advantages and disadvantages. Antibodies targeting Aβ may provide high specificity but require parenteral administration. Small molecules offer oral bioavailability but may face challenges with selectivity. Antisense oligonucleotides could provide a novel approach to modulate gene expression but require careful delivery mechanisms. PROTACs and molecular glues represent innovative strategies for targeted degradation of GSEC components but are still in early stages of development.\\n\\n**Alternative indications:**\\n\\nModulators of gamma-secretase may have alternative indications beyond Alzheimer's disease. Potential areas include:\\n\\n1. **Frontotemporal dementia (FTD):** Certain forms of FTD are associated with abnormal protein aggregation, including tau and TDP-43. Targeting GSEC may help modulate pathways involved in these aggregates.\\n\\n2. **Cognitive impairment in Down syndrome:** Individuals with Down syndrome have an increased risk of developing Alzheimer's-like pathology due to triplication of the APP gene. GSEC inhibitors could potentially mitigate cognitive decline in this population.\\n\\n3. **Other neurodegenerative diseases:** Given the role of Aβ in neuroinflammation and neuronal toxicity, GSEC modulation may have therapeutic potential in other neurodegenerative diseases characterized by protein aggregation, such as Parkinson's disease or Huntington's disease.\\n\\nIn conclusion, targeting gamma-secretase presents a compelling strategy for addressing the underlying pathology of Alzheimer's disease. The scientific rationale is supported by extensive evidence linking GSEC activity to Aβ production and subsequent neurodegeneration. Continued research and development efforts are essential to overcome the challenges associated with this target and to realize its potential in improving outcomes for patients with Alzheimer's disease and related disorders.\"]\n"
     ]
    }
   ],
   "source": [
    "print(\"Step 1: \", step_1)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Agent 1 draft: **Working hypothesis:**\n",
    "\n",
    "The working hypothesis for targeting gamma-secretase (GSEC) in Alzheimer's disease (AD) is that the inhibition of GSEC will reduce the production of amyloid-beta (Aβ) peptides, particularly the aggregation-prone forms such as Aβ42 and Aβ43, thereby mitigating the formation of amyloid plaques, a hallmark of AD pathology. Given that the accumulation of these peptides is closely linked to neurodegeneration and cognitive decline, targeting GSEC could potentially slow disease progression and improve cognitive function in affected individuals.\n",
    "\n",
    "**Unmet medical need:**\n",
    "\n",
    "Alzheimer's disease represents a significant unmet medical need, as it is the most common form of dementia, affecting millions worldwide. Current therapeutic options are limited and primarily focus on symptomatic relief rather than addressing the underlying disease mechanisms. The need for disease-modifying therapies that can effectively halt or reverse the progression of AD is critical, particularly as the aging population continues to grow.\n",
    "\n",
    "**Suitability for combination therapy:**\n",
    "\n",
    "Given the multifactorial nature of Alzheimer's disease, targeting GSEC may be suitable for combination therapy with other agents that address different aspects of the disease, such as tau pathology, neuroinflammation, or synaptic dysfunction. This approach could enhance overall therapeutic efficacy and provide a more comprehensive treatment strategy.\n",
    "\n",
    "**Predictive biomarkers:**\n",
    "\n",
    "Several predictive biomarkers exist for Alzheimer's disease that are relevant to the gamma-secretase pathway. These include:\n",
    "\n",
    "1. **Amyloid PET Imaging:** Positron emission tomography (PET) imaging with amyloid tracers can visualize amyloid plaque burden in the brain, providing a direct measure of Aβ accumulation.\n",
    "   \n",
    "2. **Cerebrospinal Fluid (CSF) Aβ Levels:** Measurement of Aβ42 and Aβ40 in CSF can indicate the presence of amyloid pathology. A lower Aβ42/Aβ40 ratio is often associated with AD.\n",
    "\n",
    "3. **Neurodegeneration Biomarkers:** Levels of tau protein and neurofilament light chain (NfL) in CSF or blood can serve as indicators of neurodegeneration and correlate with cognitive decline.\n",
    "\n",
    "4. **Genetic Risk Factors:** Genetic variants in genes such as APOE (specifically the ε4 allele) are associated with increased risk for AD and can serve as predictive biomarkers for disease susceptibility.\n",
    "\n",
    "**Clinical target rationale:**\n",
    "\n",
    "1. **Relevance of target location to disease biology:** Gamma-secretase is located in the membrane of neurons and is crucial for the processing of APP, leading to the generation of Aβ peptides. Its role in Aβ production makes it highly relevant to the pathogenesis of Alzheimer's disease.\n",
    "\n",
    "2. **Altered target expression in human disease:** Studies have shown that the expression and activity of gamma-secretase components, particularly presenilins (PS1 and PS2), are altered in AD brains. Mutations in presenilin genes are linked to familial forms of AD, further implicating GSEC in disease pathology.\n",
    "\n",
    "3. **Involvement in physiological processes:** Gamma-secretase is involved in the cleavage of several type I transmembrane proteins, influencing various signaling pathways. Its dysregulation in APP processing leads to an imbalance in Aβ production, contributing to amyloid plaque formation and neurotoxicity.\n",
    "\n",
    "4. **Phenotypes and genotypes identified for the target:** Genetic studies have identified mutations in the presenilin genes that lead to increased production of pathogenic Aβ forms. These mutations result in early-onset familial Alzheimer's disease, highlighting the direct link between GSEC activity and disease phenotype.\n",
    "\n",
    "5. **Genetic link between the target and disease:** The presence of mutations in presenilin genes in familial AD cases provides strong genetic evidence linking gamma-secretase to the disease. Additionally, polymorphisms in genes related to the Aβ pathway may influence sporadic AD risk.\n",
    "\n",
    "6. **Evidence from clinical tools:** Clinical trials targeting GSEC have shown that modulation of Aβ levels can impact cognitive outcomes. For instance, the use of GSEC inhibitors has demonstrated a reduction in Aβ levels in CSF and brain tissue, correlating with improvements in cognitive function in some studies.\n",
    "\n",
    "7. **Required target modulation:** To treat Alzheimer's disease effectively, a balanced modulation of gamma-secretase activity is required. Complete inhibition may lead to adverse effects due to the essential role of GSEC in processing other substrates. Therefore, selective modulation that reduces Aβ production while preserving normal physiological functions is desirable.\n",
    "\n",
    "**Challenges for the drug discovery program:**\n",
    "\n",
    "1. **Selectivity and safety:** Developing selective GSEC inhibitors that do not disrupt the cleavage of other important substrates is a significant challenge. Non-selective inhibition could lead to unwanted side effects.\n",
    "\n",
    "2. **Complexity of the Aβ pathway:** The Aβ production pathway is complex, with multiple enzymes involved. Understanding the interplay between GSEC and other secretases (e.g., BACE) is crucial for effective target modulation.\n",
    "\n",
    "3. **Patient heterogeneity:** Alzheimer's disease is a heterogeneous condition, and responses to GSEC modulation may vary among patients based on genetic and phenotypic differences.\n",
    "\n",
    "4. **Regulatory hurdles:** The approval process for new therapies targeting the amyloid pathway has been challenging, with recent setbacks highlighting the need for robust clinical evidence of efficacy.\n",
    "\n",
    "**Information-driven approach (IDA) strategy:**\n",
    "\n",
    "1. **Known small molecular modulators:** Several small molecule inhibitors of gamma-secretase have been developed, including semagacestat and avagacestat. However, these compounds have faced challenges in clinical trials due to adverse effects and lack of efficacy.\n",
    "\n",
    "2. **Required modulators:** For effective target modulation, a combination of inhibitors and selective modulators may be necessary. Positive allosteric modulators (PAMs) could enhance the desired effects of GSEC inhibition while minimizing side effects.\n",
    "\n",
    "3. **Patient response:** Patients with specific genetic profiles, such as those with familial AD mutations in presenilin genes, may respond more favorably to GSEC modulation. Additionally, individuals with elevated amyloid levels may be more likely to benefit from therapies targeting this pathway.\n",
    "\n",
    "4. **Commercial viability:** The proposed mode of action targeting GSEC is commercially viable, given the high unmet need in Alzheimer's disease. Successful modulation of Aβ production could lead to significant market opportunities.\n",
    "\n",
    "5. **Therapeutic modalities:** Different therapeutic modalities present various advantages and disadvantages. For example:\n",
    "   - **Antibodies:** High specificity for Aβ but may require parenteral administration.\n",
    "   - **Small molecules:** Oral bioavailability but may face challenges with selectivity.\n",
    "   - **Antisense oligonucleotides:** Target specific mRNA but may have delivery challenges.\n",
    "   - **PROTACs:** Offer targeted degradation of proteins but are still in early development stages.\n",
    "\n",
    "**Alternative indications:**\n",
    "\n",
    "Modulators of gamma-secretase may have potential in other neurodegenerative diseases characterized by protein aggregation, such as frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). In these conditions, the dysregulation of protein processing pathways may contribute to disease pathology, making GSEC a relevant target for exploration in these alternative indications. Additionally, targeting GSEC could have implications in other diseases where Aβ-like peptides are involved, such as type 2 diabetes, where amyloid deposits are observed in pancreatic islets.\n",
    "Agent 2 draft: **Working hypothesis:**\n",
    "\n",
    "The working hypothesis for targeting gamma secretase (GSEC) in Alzheimer's disease (AD) is that the inhibition of GSEC will reduce the production of amyloid-beta (Aβ) peptides, particularly the aggregation-prone forms such as Aβ42 and Aβ43, thereby mitigating the formation of amyloid plaques, which are a hallmark of AD pathology. This hypothesis is supported by the understanding that GSEC plays a critical role in the cleavage of the amyloid precursor protein (APP), leading to the generation of Aβ peptides. By modulating GSEC activity, it may be possible to alter the course of AD and improve cognitive outcomes in affected individuals.\n",
    "\n",
    "**Unmet medical need:**\n",
    "\n",
    "Alzheimer's disease represents a significant unmet medical need, as it is the most common form of dementia, affecting millions of individuals worldwide. Current therapeutic options are limited and primarily focus on symptomatic relief rather than addressing the underlying disease mechanisms. The progressive nature of AD leads to severe cognitive decline and loss of independence, highlighting the urgent need for disease-modifying therapies that can effectively target the pathophysiological processes involved in AD, particularly the accumulation of amyloid plaques.\n",
    "\n",
    "**Combination therapy suitability:**\n",
    "\n",
    "Given the multifactorial nature of Alzheimer's disease, targeting GSEC may be suitable for combination therapy with other agents that address different aspects of the disease, such as tau pathology or neuroinflammation. Combining GSEC inhibitors with other therapeutic modalities could enhance overall efficacy and provide a more comprehensive approach to treatment.\n",
    "\n",
    "**Predictive biomarkers:**\n",
    "\n",
    "Several predictive biomarkers exist that are relevant to the target and the pathogenesis of Alzheimer's disease. These include:\n",
    "\n",
    "1. **Amyloid PET Imaging:** Positron emission tomography (PET) imaging using amyloid tracers (e.g., [11C]PiB) can visualize amyloid plaque deposition in the brain, providing a direct measure of the pathological hallmark of AD.\n",
    "\n",
    "2. **Cerebrospinal Fluid (CSF) Biomarkers:** The levels of Aβ42, total tau, and phosphorylated tau in CSF are established biomarkers for AD. A decrease in Aβ42 levels, along with an increase in tau levels, is indicative of AD pathology.\n",
    "\n",
    "3. **Genetic Biomarkers:** Variants in genes such as APOE (particularly the ε4 allele) are associated with an increased risk of developing AD and can serve as predictive biomarkers for disease susceptibility.\n",
    "\n",
    "**Clinical target rationale:**\n",
    "\n",
    "1. **Target location relevance:** Gamma secretase is located in the membrane of neurons and glial cells, where it cleaves APP and other substrates. Its localization is highly relevant to the pathogenesis of AD, as the generation of Aβ occurs at the synaptic level, influencing neuronal health and function.\n",
    "\n",
    "2. **Altered target expression:** Studies have shown that the expression of gamma secretase components, particularly presenilins (PS1 and PS2), is altered in AD brains. Mutations in presenilin genes are linked to familial forms of AD, underscoring the importance of GSEC in the disease.\n",
    "\n",
    "3. **Physiological involvement:** Gamma secretase is involved in the physiological processing of various type I transmembrane proteins, including Notch, which plays a role in cell signaling and neurogenesis. Dysregulation of GSEC can lead to both increased Aβ production and impaired Notch signaling, contributing to neurodegeneration.\n",
    "\n",
    "4. **Phenotypes and genotypes:** Genetic studies have identified several mutations in the APP and presenilin genes that lead to increased Aβ production and early-onset familial AD. These genetic links provide strong evidence for the role of GSEC in AD pathogenesis.\n",
    "\n",
    "5. **Clinical evidence:** Clinical trials targeting GSEC have shown mixed results, with some inhibitors demonstrating a reduction in Aβ levels in CSF and brain tissue. However, the challenge remains to achieve a balance between reducing Aβ production and maintaining the physiological functions of GSEC.\n",
    "\n",
    "6. **Target modulation requirements:** Effective treatment of AD may require partial inhibition of GSEC to reduce Aβ production while preserving its function in processing other substrates. This necessitates a careful modulation strategy to avoid adverse effects.\n",
    "\n",
    "**Challenges for the drug discovery program:**\n",
    "\n",
    "1. **Selectivity and specificity:** Developing GSEC inhibitors that selectively target Aβ production without affecting other critical pathways regulated by GSEC, such as Notch signaling, poses a significant challenge.\n",
    "\n",
    "2. **Safety and tolerability:** Inhibition of GSEC may lead to unintended consequences, including potential neurotoxicity or disruption of normal cellular processes, necessitating thorough safety evaluations in clinical trials.\n",
    "\n",
    "3. **Patient heterogeneity:** Alzheimer's disease is a heterogeneous condition, and individual patient responses to GSEC modulation may vary based on genetic and environmental factors.\n",
    "\n",
    "**Information-driven approach (IDA):**\n",
    "\n",
    "1. **Known small molecular modulators:** Several small molecule inhibitors of GSEC have been developed, including compounds like semagacestat and avagacestat. However, these have faced challenges in clinical trials due to adverse effects.\n",
    "\n",
    "2. **Required modulators:** A combination of inhibitors, antagonists, and possibly positive allosteric modulators may be required to achieve the desired modulation of GSEC activity while minimizing side effects.\n",
    "\n",
    "3. **Patient response:** Patients with early-stage AD or those with specific genetic risk factors (e.g., APOE ε4 carriers) may be more likely to respond to GSEC-targeted therapies.\n",
    "\n",
    "4. **Commercial viability:** The proposed mode of action targeting GSEC is commercially viable, given the significant market potential for effective AD therapies. However, the competitive landscape and regulatory hurdles must be considered.\n",
    "\n",
    "5. **Therapeutic modalities:** Different therapeutic modalities present various advantages and disadvantages. Small molecules may offer oral bioavailability and ease of administration, while monoclonal antibodies may provide higher specificity but require intravenous administration. Antisense oligonucleotides could offer a novel approach to modulate gene expression, but delivery to the central nervous system remains a challenge.\n",
    "\n",
    "**Alternative indications:**\n",
    "\n",
    "Modulators of gamma secretase may have potential in other neurodegenerative diseases characterized by protein aggregation, such as frontotemporal dementia (FTD) or amyotrophic lateral sclerosis (ALS). The commonality of protein misfolding and aggregation in these conditions suggests that GSEC modulation could be beneficial in reducing toxic protein species and improving neuronal health. Additionally, targeting GSEC may have implications in cancer biology, where Notch signaling plays a critical role in tumorigenesis, presenting an opportunity for dual-targeting strategies in oncology.\n",
    "Agent 3 draft: **Working hypothesis:**\n",
    "\n",
    "The working hypothesis for targeting gamma-secretase (GSEC) in Alzheimer's disease (AD) is that modulation of this multi-subunit protease complex can effectively reduce the production of amyloid-beta (Aβ) peptides, particularly the aggregation-prone forms such as Aβ42 and Aβ43, thereby mitigating the formation of amyloid plaques that are characteristic of AD pathology. The hypothesis posits that by inhibiting GSEC activity, the downstream effects of Aβ aggregation, neuroinflammation, and neuronal toxicity can be alleviated, leading to improved cognitive function and a potential slowing of disease progression.\n",
    "\n",
    "**Unmet medical need:**\n",
    "\n",
    "Alzheimer's disease represents a significant unmet medical need, with millions of individuals affected globally. Current therapeutic options are limited and primarily focus on symptomatic relief rather than addressing the underlying pathophysiology. The need for disease-modifying therapies that can effectively target the amyloid cascade hypothesis remains critical, as existing treatments do not halt or reverse the cognitive decline associated with AD. The development of GSEC inhibitors could fulfill this need by directly targeting the source of Aβ production.\n",
    "\n",
    "**Suitability for combination therapy:**\n",
    "\n",
    "Given the multifactorial nature of Alzheimer's disease, GSEC inhibitors may be suitable for combination therapy with other modalities targeting different aspects of the disease, such as tau pathology, neuroinflammation, or cholinergic deficits. Combining GSEC inhibition with agents that enhance synaptic function or reduce neuroinflammation could provide a synergistic effect, potentially leading to better clinical outcomes.\n",
    "\n",
    "**Predictive biomarkers:**\n",
    "\n",
    "Several predictive biomarkers exist that are relevant to the modulation of gamma-secretase in Alzheimer's disease. These include:\n",
    "\n",
    "1. **Amyloid PET Imaging:** Positron emission tomography (PET) imaging with amyloid tracers (e.g., [11C]PiB) can visualize amyloid plaque burden in the brain, providing a direct measure of Aβ accumulation.\n",
    "\n",
    "2. **Cerebrospinal Fluid (CSF) Aβ Levels:** Measurement of Aβ42 and Aβ40 levels in CSF can serve as a biomarker for GSEC activity, as alterations in these levels reflect changes in amyloid processing.\n",
    "\n",
    "3. **Neurodegeneration Biomarkers:** Levels of neurodegeneration markers such as total tau (t-tau) and phosphorylated tau (p-tau) in CSF can indicate the downstream effects of Aβ accumulation and neuronal damage.\n",
    "\n",
    "4. **Genetic Risk Factors:** Genetic variants in genes related to amyloid processing, such as APOE ε4 allele, can serve as predictive biomarkers for disease risk and progression.\n",
    "\n",
    "**Clinical target rationale:**\n",
    "\n",
    "1. **Target location relevance:** Gamma-secretase is located in the membrane of neurons and glial cells, where it plays a crucial role in the processing of APP and the generation of Aβ peptides. Its localization is directly relevant to the pathogenesis of Alzheimer's disease, as the accumulation of Aβ in the brain is a hallmark of the disease.\n",
    "\n",
    "2. **Altered target expression:** Studies have shown that the expression levels of gamma-secretase components, particularly presenilins (PS1 and PS2), are altered in the brains of AD patients. Increased activity of GSEC has been associated with higher levels of toxic Aβ42, indicating a direct link between target expression and disease pathology.\n",
    "\n",
    "3. **Physiological process involvement:** Gamma-secretase is involved in the cleavage of various type I transmembrane proteins beyond APP, including Notch receptors, which are essential for cell signaling and neuronal health. Dysregulation of GSEC can lead to both increased Aβ production and impaired Notch signaling, contributing to neurodegeneration.\n",
    "\n",
    "4. **Phenotypes and genotypes:** Genetic mutations in presenilin genes (PSEN1 and PSEN2) are known to cause familial forms of Alzheimer's disease, leading to early-onset AD. These mutations often result in altered GSEC activity, producing a higher ratio of Aβ42 to Aβ40, which is associated with increased amyloid plaque formation.\n",
    "\n",
    "5. **Genetic link evidence:** The genetic association between GSEC and Alzheimer's disease is well-established, with numerous studies linking mutations in presenilin genes to familial AD. Additionally, polymorphisms in genes related to Aβ metabolism have been implicated in sporadic AD cases.\n",
    "\n",
    "6. **Clinical evidence:** Clinical trials targeting GSEC have shown that modulation of Aβ levels can influence cognitive outcomes. For instance, GSEC inhibitors have demonstrated the ability to lower Aβ levels in CSF and reduce amyloid plaque burden in preclinical models, providing a rationale for their potential efficacy in humans.\n",
    "\n",
    "7. **Target modulation requirements:** To effectively treat Alzheimer's disease, a balanced modulation of gamma-secretase is required. Complete inhibition may lead to adverse effects due to the essential role of GSEC in processing other substrates, such as Notch. Therefore, selective inhibitors that preferentially reduce Aβ production while preserving normal GSEC function are desirable.\n",
    "\n",
    "**Challenges for the drug discovery program:**\n",
    "\n",
    "1. **Selectivity and safety:** Developing selective GSEC inhibitors that do not disrupt the processing of other critical substrates poses a significant challenge. Inhibition of Notch signaling can lead to unwanted side effects, including impaired neurogenesis and cognitive function.\n",
    "\n",
    "2. **Heterogeneity of Alzheimer's disease:** The variability in disease pathology among patients complicates the identification of a one-size-fits-all therapeutic approach. Personalized medicine strategies may be necessary to optimize treatment based on individual patient profiles.\n",
    "\n",
    "3. **Clinical trial design:** Designing clinical trials that adequately assess the efficacy of GSEC inhibitors in a heterogeneous patient population while accounting for the multifactorial nature of AD is complex.\n",
    "\n",
    "4. **Regulatory hurdles:** Gaining regulatory approval for new therapies targeting the amyloid pathway has been challenging, as seen with recent controversies surrounding amyloid-targeting drugs.\n",
    "\n",
    "**Information-driven approach (IDA) strategy:**\n",
    "\n",
    "1. **Small molecular modulators:** Several small molecule modulators of gamma-secretase have been identified, including compounds that selectively inhibit the production of Aβ42 while sparing Aβ40. Examples include semagacestat and avagacestat, although they faced challenges in clinical development.\n",
    "\n",
    "2. **Required modulators:** For effective target modulation, a combination of inhibitors and selective modulators may be required. Negative allosteric modulators (NAMs) that reduce GSEC activity without complete inhibition could be explored, as well as positive allosteric modulators (PAMs) that enhance the processing of non-amyloidogenic pathways.\n",
    "\n",
    "3. **Patient response:** Patients with elevated levels of Aβ42 or those with genetic predispositions to AD may be more likely to respond to GSEC-targeted therapies. Biomarker-driven patient selection could enhance the likelihood of therapeutic success.\n",
    "\n",
    "4. **Commercial viability:** The proposed mode of action targeting GSEC is commercially viable, given the high unmet need in Alzheimer's disease. Successful modulation of Aβ production could lead to significant market opportunities, especially if combined with other therapeutic strategies.\n",
    "\n",
    "5. **Therapeutic modalities:** Different therapeutic modalities present advantages and disadvantages. Antibodies targeting Aβ may provide high specificity but require parenteral administration. Small molecules offer oral bioavailability but may face challenges with selectivity. Antisense oligonucleotides could provide a novel approach to modulate gene expression but require careful delivery mechanisms. PROTACs and molecular glues represent innovative strategies for targeted degradation of GSEC components but are still in early stages of development.\n",
    "\n",
    "**Alternative indications:**\n",
    "\n",
    "Modulators of gamma-secretase may have alternative indications beyond Alzheimer's disease. Potential areas include:\n",
    "\n",
    "1. **Frontotemporal dementia (FTD):** Certain forms of FTD are associated with abnormal protein aggregation, including tau and TDP-43. Targeting GSEC may help modulate pathways involved in these aggregates.\n",
    "\n",
    "2. **Cognitive impairment in Down syndrome:** Individuals with Down syndrome have an increased risk of developing Alzheimer's-like pathology due to triplication of the APP gene. GSEC inhibitors could potentially mitigate cognitive decline in this population.\n",
    "\n",
    "3. **Other neurodegenerative diseases:** Given the role of Aβ in neuroinflammation and neuronal toxicity, GSEC modulation may have therapeutic potential in other neurodegenerative diseases characterized by protein aggregation, such as Parkinson's disease or Huntington's disease.\n",
    "\n",
    "In conclusion, targeting gamma-secretase presents a compelling strategy for addressing the underlying pathology of Alzheimer's disease. The scientific rationale is supported by extensive evidence linking GSEC activity to Aβ production and subsequent neurodegeneration. Continued research and development efforts are essential to overcome the challenges associated with this target and to realize its potential in improving outcomes for patients with Alzheimer's disease and related disorders."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "def get_query(question, system_prompt):\n",
    "\n",
    "    \"\"\"writes a query for the API based on the \n",
    "    user prompt(question) and system prompt\"\"\"\n",
    "    \n",
    "    question = question\n",
    "\n",
    "    query = openai.chat.completions.create(\n",
    "        model = \"gpt-4o-mini\",\n",
    "        messages=[\n",
    "            {\n",
    "                \"role\": \"system\",\n",
    "                \"content\": system_prompt\n",
    "            },\n",
    "            {\n",
    "                \"role\": \"user\",\n",
    "                \"content\": question\n",
    "            }\n",
    "        ],\n",
    "        temperature=0.2\n",
    "    ).choices[0].message.content\n",
    "    \n",
    "    return query"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "import openai\n",
    "\n",
    "def refine_drafts(question, initial_drafts, num_steps=3):\n",
    "    refined_answers = []\n",
    "    previous_answer = \"\\n\\n\".join(initial_drafts)\n",
    "\n",
    "    for step in range(num_steps):\n",
    "        print(f\"Refinement step {step + 1}/{num_steps}\")\n",
    "\n",
    "        refine_prompt = f'''\n",
    "Based on the question and the previous answer, expand and refine the response. Add more details, correct any errors, and make the answer more comprehensive and well-structured.\n",
    "\n",
    "Question: {question}\n",
    "\n",
    "Previous Answer: {previous_answer}\n",
    "\n",
    "IMPORTANT:\n",
    "- Provide a step-by-step, well-structured answer.\n",
    "- Use `\\n\\n` to split the answer into paragraphs.\n",
    "- Directly respond to the question without additional explanations or introductions.\n",
    "- Integrate and improve upon the information from the previous answer.\n",
    "'''\n",
    "\n",
    "        refined_answer = openai.chat.completions.create(\n",
    "            model=\"gpt-3.5-turbo\",\n",
    "            messages=[\n",
    "                {\n",
    "                    \"role\": \"system\",\n",
    "                    \"content\": \"You are a helpful assistant tasked with refining and improving answers.\"\n",
    "                },\n",
    "                {\n",
    "                    \"role\": \"user\",\n",
    "                    \"content\": refine_prompt\n",
    "                }\n",
    "            ],\n",
    "            temperature=0.7\n",
    "        ).choices[0].message.content\n",
    "\n",
    "        refined_answers.append(f\"Refinement Step {step + 1}:\\n{refined_answer}\")\n",
    "        previous_answer = refined_answer\n",
    "\n",
    "    return refined_answers\n",
    "\n",
    "# Example usage\n",
    "question = \"Explain the concept of artificial intelligence.\"\n",
    "initial_drafts = get_initial_drafts(question, num_agents=3)\n",
    "refined_answers = refine_drafts(question, initial_drafts, num_steps=3)\n",
    "\n",
    "# Print each refined answer\n",
    "for refined in refined_answers:\n",
    "    print(refined)\n",
    "    print(\"---\")"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "LLM_agent",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.4"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
